ZIKV IG
Alternative Names: NP024; Zika antibody therapeutic; Zika-virus-antibodies-Emergent-Biosolutions; Zika-virus-immunotherapy-Emergent-Biosolutions; ZIKV-IGLatest Information Update: 28 Aug 2021
At a glance
- Originator Emergent BioSolutions
- Class Antibodies; Antivirals; Immunoglobulins; Immunotherapies; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention) in Canada (IV)
- 06 Mar 2019 Emergent BioSolutions completes a phase I trial in Zika virus infection in Canada (NCT03624946)
- 30 Jul 2018 Phase-I clinical trials in Zika virus infection (Prevention) in Canada (IV) (NCT03624946)